How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/prevention-of-glucocorticoid-induced-osteoporosis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Prevention of Glucocorticoid-Induced Osteoporosis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of Glucocorticoid-Induced Osteoporosis (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of Glucocorticoid-Induced Osteoporosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zometa	ZOLEDRONIC ACID	Novartis	zoledronic acid	Farnesyl pyrophosphate synthase	2001-01-01
Fosamax	ALENDRONIC ACID	Merck And Co Inc	Vitamin D [EPC]	Farnesyl pyrophosphate synthase	1995-01-01
Risedronate	Risedronate	Toronto Rehabilitation Institute		Butyrophilin subfamily 3 member A1, Farnesyl pyrophosphate synthase, Farnesyl diphosphate synthase
alendronate	alendronate	Massachusetts General Hospital		Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, EC 2.5.1.1, EC 2.5.1.10
Zometa	Zometa	University of Arkansas		Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase
Zoledronate	Zoledronate	Children's Hospital Medical Center, Cincinnati		Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Children's Hospital Medical Center, Cincinnati · 1 drug in Prevention of Glucocorticoid-Induced Osteoporosis
Massachusetts General Hospital · 1 drug in Prevention of Glucocorticoid-Induced Osteoporosis
Merck And Co Inc · 1 drug in Prevention of Glucocorticoid-Induced Osteoporosis
Novartis · 1 drug in Prevention of Glucocorticoid-Induced Osteoporosis
Toronto Rehabilitation Institute · 1 drug in Prevention of Glucocorticoid-Induced Osteoporosis
University of Arkansas · 1 drug in Prevention of Glucocorticoid-Induced Osteoporosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of Glucocorticoid-Induced Osteoporosis:

Cite this brief

Drug Landscape (2026). Prevention of Glucocorticoid-Induced Osteoporosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-glucocorticoid-induced-osteoporosis. Accessed 2026-06-10.

Prevention of Glucocorticoid-Induced Osteoporosis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing